Second Sight Medical Products Inc
EYES
Get informed when a big investor buys or sells
+ FollowMarket Cap$210.05M
Close$
$7.52
81.7% upside
Current Fair Value
81.7% upsideUndervalued by 81.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $210.05 Million |
|---|---|
| Enterprise Value | $208.57 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.43 |
| Beta | 2.56 |
| Outstanding Shares | 81,269,000 |
Return
| Return on Equity | -141.93% |
|---|---|
| Return on Assets | -63.96% |
| Return on Invested Capital | -78.18% |
Valuation & Multiples
| P/E Ratio | -0.66 |
|---|---|
| PEG | -8.69 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.5 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.96 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Second Sight Medical Products Inc
12 employeesSecond Sight Medical Products, Inc. (NASDAQ: EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulatio...